Better Health: Smart Health Commentary Better Health (TM): smart health commentary

Article Comments

The Problem Of Drug Extinction

Doctors are all-familiar with marketing efforts to promote new drugs, but once the new drugs displace older drugs in the medical marketplace, who serves as advocates for the continued manufacturing of older FDA-approved drugs?

In a short answer: No one.

For those of us dealing in cardiac arrhythmia management, this presents difficult challenges for patient care if people are unable to take the newer drugs due to side effects. These patients no longer have a fall-back option to turn to for medical therapy when the older drugs have become extinct on the marketplace.

Examples of antiarrhythmics that have reached extinction status in the U.S. include many of our older antiarrhythmic drugs such as procainamide, mexilentine or quinaglute.

Take for instance a recent case:

A older person with recurrent ventricular tachycardia and congestive heart failure and ICD implantation who has experienced several appropriate shocks for hemodynamically-significant ventricular tachycardia from their ICD. They were not in heart failure and had a consistent ideal body weight. Beta blocker medications have been maximized. This same person is pacemaker dependent and allergic to Amiodarone and iodine. Sotalol was not tolerated and dronedarone is contraindicated because of heart failure. Their creatinine clearance is 40. The patient was placed on mexilentine in the hospital and did well, only to find after discharge that pharmacies could no longer obtain the drug. Oral procainamide, I have found, suffered the same fate long ago. Few options remain: dofetilide as an inpatient?

Perhaps.

Still, the issue of drug extinction is a challenging one: not enough market to justify the drug’s manufacture, yet still a rare patient out there who might need an older medication. Even generic drug manufacturers won’t manufacture these niche drugs — there’s just not enough of a market to justify their manufacture and the regulatory environment precludes a small startup company from even trying to meet the very small demand.

I wish I had an answer to this conundrum. How do others handle this situation?

-WesMusings of a cardiologist and cardiac electrophysiologist.

*This blog post was originally published at Dr. Wes*


You may also like these posts

Read comments »


Comments are closed.

Return to article »

Latest Interviews

IDEA Labs: Medical Students Take The Lead In Healthcare Innovation

It’s no secret that doctors are disappointed with the way that the U.S. healthcare system is evolving. Most feel helpless about improving their work conditions or solving technical problems in patient care. Fortunately one young medical student was undeterred by the mountain of disappointment carried by his senior clinician mentors…

Read more »

How To Be A Successful Patient: Young Doctors Offer Some Advice

I am proud to be a part of the American Resident Project an initiative that promotes the writing of medical students residents and new physicians as they explore ideas for transforming American health care delivery. I recently had the opportunity to interview three of the writing fellows about how to…

Read more »

See all interviews »

Latest Cartoon

See all cartoons »

Latest Book Reviews

Book Review: Is Empathy Learned By Faking It Till It’s Real?

I m often asked to do book reviews on my blog and I rarely agree to them. This is because it takes me a long time to read a book and then if I don t enjoy it I figure the author would rather me remain silent than publish my…

Read more »

The Spirit Of The Place: Samuel Shem’s New Book May Depress You

When I was in medical school I read Samuel Shem s House Of God as a right of passage. At the time I found it to be a cynical yet eerily accurate portrayal of the underbelly of academic medicine. I gained comfort from its gallows humor and it made me…

Read more »

Eat To Save Your Life: Another Half-True Diet Book

I am hesitant to review diet books because they are so often a tangled mess of fact and fiction. Teasing out their truth from falsehood is about as exhausting as delousing a long-haired elementary school student. However after being approached by the authors’ PR agency with the promise of a…

Read more »

See all book reviews »